我要投票 香雪在中草药行业中的票数:221
· 外 推 电 报 ·
2025-03-10 23:34:04 星期一

【香雪是哪个国家的品牌?】

香雪是什么牌子?「香雪」是 广州市香雪制药股份有限公司 旗下著名品牌。该品牌发源于广东,由创始人王永辉在1986期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力香雪品牌出海!通过在本页面挂载香雪品牌的产品链接和联系邮箱,可以提高香雪产品曝光!跨境电商爆单神器,目前只要100元/年哦~

广州市香雪制药股份有限公司总部位于广州经济技术开发区科学城,是一家以中成药制药和研发为主业,集西药制药、生物医学工程和药材规范种植于一体的现代化高新技术医药企业。

公司秉承“厚生臻善维新”的企业理念,坚持“崇尚品质;关爱健康”的质量方针,坚持自主创新、自主品牌,在品质、技术、研发、品牌和规模等多方面成长为行业领先者,得到消费者、行业和政府主管部门的高度评价和广泛认可,其中“香雪”商标获评中国驰名商标,“香雪抗病毒口服液”获评广东省名牌和广州市名牌产品,香雪制药获评“《福布斯》中国成长企业潜力榜100强”前五位,香雪制药获评“广东省医药产业50强企业”和“广州2010年亚运会药品供应商”等。

香雪制药一直致力于质量创新,致力于中药现代化的研究和实践,1998年开始进行中药现代化关键技术指纹图谱质量控制技术的研究,并取得重大突破。2001年,香雪抗病毒口服液指纹图谱质控研究被纳入广州名优中成药品种指纹图谱质量控制示范研究项目。2000年,香雪制药本着“实施中药系列标准规范,提高中成药品种质量”的理念,承担了国家科技部的“九五”重点科技攻关项目广藿香GAP种植基地,经过一年多的探索与研究,现已被国家科技部列入第一批国家中药现代化科技产业化(广东)基地,并通过国家验收。

香雪制药本着高起点、高技术、高标准、高速度的现代企业发展战略,采用先进的技术、工艺、设备,形成了完善、科学、先进的生产体系,使公司的产品质量和主要技术指标均达到了国内先进水平。公司坚持“创新”为企业的灵魂,以科技进步推动企业的发展。近年来承担了多项国家及省、市级重大科技专项技术的研究与开发;本着生产一代、储备一代、研制一代、构思一代的新产品开发战略。加快了疗效确切、科技含量高的新产品的研制开发。

英文翻译:Guangzhou Xiangxue Pharmaceutical Co., Ltd., headquartered in Science City, Guangzhou Economic and Technological Development Zone, is a modern high-tech pharmaceutical enterprise with Chinese patent medicine and R & D as its main business, integrating western medicine, biomedical engineering and standard planting of medicinal materials. The company adheres to the enterprise concept of "great life, perfect and innovative", and adheres to "advocating quality"; The company adheres to the quality policy of "care for health", adheres to independent innovation and independent brand, grows into the industry leader in quality, technology, R & D, brand and scale, and is highly appraised and widely recognized by consumers, industry and government authorities. Among them, "Xiangxue" trademark is awarded the famous trademark in China, and "Xiangxue antiviral oral liquid" is awarded the famous brand in Guangdong Province and Guangzhou city Brand products, Xiangxue pharmaceutical won the top five "Forbes China growth enterprise potential list top 100", Xiangxue pharmaceutical won the "top 50 pharmaceutical enterprises in Guangdong Province" and "drug supplier of Guangzhou 2010 Asian Games" and so on. Xiangxue pharmaceutical has been committed to quality innovation, research and practice of the modernization of traditional Chinese medicine. In 1998, it began to study the key technology of the modernization of traditional Chinese medicine fingerprint quality control technology, and made a major breakthrough. In 2001, the fingerprint quality control research of Xiangxue antiviral oral liquid was included in the quality control demonstration research project of Guangzhou famous and excellent Chinese patent medicine. In 2000, in line with the concept of "implementing the standards and specifications of traditional Chinese medicine series and improving the quality of traditional Chinese medicine varieties", Xiangxue pharmaceutical undertook the patchouli gap planting base, a key scientific and technological key project of the Ninth Five Year Plan of the Ministry of science and technology of the people's Republic of China. After more than a year's exploration and research, it has been listed in the first batch of national bases for the modernization of science and technology industrialization of traditional Chinese medicine (Guangdong) by the Ministry of science and technology of the people's Republic of China and passed the national acceptance 。 Based on the modern enterprise development strategy of high starting point, high technology, high standard and high speed, Xiangxue pharmaceutical adopts advanced technology, process and equipment to form a perfect, scientific and advanced production system, so that the product quality and main technical indicators of the company have reached the advanced level in China. The company adheres to "innovation" as the soul of the enterprise and promotes the development of the enterprise with the progress of science and technology. In recent years, it has undertaken the research and development of a number of national, provincial and municipal major science and technology special technologies; in line with the new product development strategy of production generation, storage generation, development generation and conception generation. The research and development of new products with precise curative effect and high technology content are accelerated.

本文链接: https://www.waitui.com/brand/f0447df2d.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

我国科学家在抗烧结催化剂研究中取得新进展

36氪获悉,据中国科学技术大学消息,该校曾杰教授团队通过构筑纳米岛结构催化剂,攻克了甲烷干重整反应中催化剂极易烧结失活的难题。相关研究成果3月10日发表于国际学术期刊《自然∙材料》。超细金属纳米颗粒因其超高的原子利用率,在多相催化领域备受青睐。然而,在催化反应过程中,这些纳米颗粒极易受到高温等影响,从而自发聚集并导致活性降低,该过程被称作烧结。发展超细金属纳米颗粒的抗烧结策略,是催化科学领域亟待解决的关键难题。

2小时前

蔚蓝锂芯:2024年净利润4.88亿元,同比增长246.43%

36氪获悉,蔚蓝锂芯公告,公司实现营业总收入67.56亿元,同比增长29.38%;实现净利润5.44亿元,同比增长171.98%;归属于上市公司股东的净利润4.88亿元,同比增长246.43%。公司拟以2024年12月31日总股本1,152,046,537股为基数,向全体股东每10股派发现金红利0.65元(含税)。

2小时前

美股大型科技股盘前全线下跌,特斯拉跌超3%

36氪获悉,美股大型科技股盘前全线下跌,截至发稿,特斯拉、Arm跌超3%,英伟达、亚马逊、谷歌、Meta跌超2%,苹果、微软、奈飞跌超1%。

2小时前

热门中概股美股盘前普跌,B站跌超4%

36氪获悉,热门中概股美股盘前普跌,截至发稿,B站跌超4%,阿里巴巴跌超3%,京东、爱奇艺、腾讯音乐、蔚来、理想汽车、小鹏汽车跌超2%,拼多多、百度跌超1%。

2小时前

新产业:红杉聚业拟减持不超1%公司股份

36氪获悉,新产业公告,公司持股5%以上的股东天津红杉聚业股权投资合伙企业(有限合伙)计划自公告之日起15个交易日后的3个月内通过大宗交易方式减持公司股份不超过总股本的1%。若公司在减持计划实施期间发生送股、资本公积转增股本、配股等变动事项,减持股份数量进行相应调整。减持原因为自身资金需求。

2小时前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询